定期服用鱼油补充剂与心血管疾病的病程:前瞻性队列研究。

BMJ medicine Pub Date : 2024-05-21 eCollection Date: 2024-01-01 DOI:10.1136/bmjmed-2022-000451
Ge Chen, Zhengmin Min Qian, Junguo Zhang, Shiyu Zhang, Zilong Zhang, Michael G Vaughn, Hannah E Aaron, Chuangshi Wang, Gregory Yh Lip, Hualiang Lin
{"title":"定期服用鱼油补充剂与心血管疾病的病程:前瞻性队列研究。","authors":"Ge Chen, Zhengmin Min Qian, Junguo Zhang, Shiyu Zhang, Zilong Zhang, Michael G Vaughn, Hannah E Aaron, Chuangshi Wang, Gregory Yh Lip, Hualiang Lin","doi":"10.1136/bmjmed-2022-000451","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>To examine the effects of fish oil supplements on the clinical course of cardiovascular disease, from a healthy state to atrial fibrillation, major adverse cardiovascular events, and subsequently death.</p><p><strong>Design: </strong>Prospective cohort study.</p><p><strong>Setting: </strong>UK Biobank study, 1 January 2006 to 31 December 2010, with follow-up to 31 March 2021 (median follow-up 11.9 years).</p><p><strong>Participants: </strong>415 737 participants, aged 40-69 years, enrolled in the UK Biobank study.</p><p><strong>Main outcome measures: </strong>Incident cases of atrial fibrillation, major adverse cardiovascular events, and death, identified by linkage to hospital inpatient records and death registries. Role of fish oil supplements in different progressive stages of cardiovascular diseases, from healthy status (primary stage), to atrial fibrillation (secondary stage), major adverse cardiovascular events (tertiary stage), and death (end stage).</p><p><strong>Results: </strong>Among 415 737 participants free of cardiovascular diseases, 18 367 patients with incident atrial fibrillation, 22 636 with major adverse cardiovascular events, and 22 140 deaths during follow-up were identified. Regular use of fish oil supplements had different roles in the transitions from healthy status to atrial fibrillation, to major adverse cardiovascular events, and then to death. For people without cardiovascular disease, hazard ratios were 1.13 (95% confidence interval 1.10 to 1.17) for the transition from healthy status to atrial fibrillation and 1.05 (1.00 to 1.11) from healthy status to stroke. For participants with a diagnosis of a known cardiovascular disease, regular use of fish oil supplements was beneficial for transitions from atrial fibrillation to major adverse cardiovascular events (hazard ratio 0.92, 0.87 to 0.98), atrial fibrillation to myocardial infarction (0.85, 0.76 to 0.96), and heart failure to death (0.91, 0.84 to 0.99).</p><p><strong>Conclusions: </strong>Regular use of fish oil supplements might be a risk factor for atrial fibrillation and stroke among the general population but could be beneficial for progression of cardiovascular disease from atrial fibrillation to major adverse cardiovascular events, and from atrial fibrillation to death. Further studies are needed to determine the precise mechanisms for the development and prognosis of cardiovascular disease events with regular use of fish oil supplements.</p>","PeriodicalId":72433,"journal":{"name":"BMJ medicine","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2024-05-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11116879/pdf/","citationCount":"0","resultStr":"{\"title\":\"Regular use of fish oil supplements and course of cardiovascular diseases: prospective cohort study.\",\"authors\":\"Ge Chen, Zhengmin Min Qian, Junguo Zhang, Shiyu Zhang, Zilong Zhang, Michael G Vaughn, Hannah E Aaron, Chuangshi Wang, Gregory Yh Lip, Hualiang Lin\",\"doi\":\"10.1136/bmjmed-2022-000451\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Objective: </strong>To examine the effects of fish oil supplements on the clinical course of cardiovascular disease, from a healthy state to atrial fibrillation, major adverse cardiovascular events, and subsequently death.</p><p><strong>Design: </strong>Prospective cohort study.</p><p><strong>Setting: </strong>UK Biobank study, 1 January 2006 to 31 December 2010, with follow-up to 31 March 2021 (median follow-up 11.9 years).</p><p><strong>Participants: </strong>415 737 participants, aged 40-69 years, enrolled in the UK Biobank study.</p><p><strong>Main outcome measures: </strong>Incident cases of atrial fibrillation, major adverse cardiovascular events, and death, identified by linkage to hospital inpatient records and death registries. Role of fish oil supplements in different progressive stages of cardiovascular diseases, from healthy status (primary stage), to atrial fibrillation (secondary stage), major adverse cardiovascular events (tertiary stage), and death (end stage).</p><p><strong>Results: </strong>Among 415 737 participants free of cardiovascular diseases, 18 367 patients with incident atrial fibrillation, 22 636 with major adverse cardiovascular events, and 22 140 deaths during follow-up were identified. Regular use of fish oil supplements had different roles in the transitions from healthy status to atrial fibrillation, to major adverse cardiovascular events, and then to death. For people without cardiovascular disease, hazard ratios were 1.13 (95% confidence interval 1.10 to 1.17) for the transition from healthy status to atrial fibrillation and 1.05 (1.00 to 1.11) from healthy status to stroke. For participants with a diagnosis of a known cardiovascular disease, regular use of fish oil supplements was beneficial for transitions from atrial fibrillation to major adverse cardiovascular events (hazard ratio 0.92, 0.87 to 0.98), atrial fibrillation to myocardial infarction (0.85, 0.76 to 0.96), and heart failure to death (0.91, 0.84 to 0.99).</p><p><strong>Conclusions: </strong>Regular use of fish oil supplements might be a risk factor for atrial fibrillation and stroke among the general population but could be beneficial for progression of cardiovascular disease from atrial fibrillation to major adverse cardiovascular events, and from atrial fibrillation to death. Further studies are needed to determine the precise mechanisms for the development and prognosis of cardiovascular disease events with regular use of fish oil supplements.</p>\",\"PeriodicalId\":72433,\"journal\":{\"name\":\"BMJ medicine\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-05-21\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11116879/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"BMJ medicine\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1136/bmjmed-2022-000451\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"BMJ medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1136/bmjmed-2022-000451","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

目的:研究鱼油补充剂对心血管疾病临床过程的影响:研究鱼油补充剂对心血管疾病临床过程的影响,包括从健康状态到心房颤动、主要不良心血管事件以及随后的死亡:前瞻性队列研究:英国生物库研究,2006 年 1 月 1 日至 2010 年 12 月 31 日,随访至 2021 年 3 月 31 日(中位数随访 11.9 年):415 737名参与者,年龄在40-69岁之间,参加了英国生物库研究:主要结果测量指标:心房颤动、主要不良心血管事件和死亡的发生病例,通过与医院住院病人记录和死亡登记的连接来确定。鱼油补充剂在心血管疾病的不同进展阶段(从健康状态(初级阶段)到心房颤动(二级阶段)、重大不良心血管事件(三级阶段)和死亡(终末阶段))中的作用:在 415 737 名无心血管疾病的参与者中,发现了 18 367 名心房颤动患者、22 636 名心血管重大不良事件患者和 22 140 名在随访期间死亡的患者。在从健康状态到心房颤动、到主要不良心血管事件、再到死亡的转变过程中,定期服用鱼油补充剂起到了不同的作用。对于没有心血管疾病的人来说,从健康状态过渡到心房颤动的危险比为 1.13(95% 置信区间为 1.10 至 1.17),从健康状态过渡到中风的危险比为 1.05(1.00 至 1.11)。对于确诊患有已知心血管疾病的参与者,定期服用鱼油补充剂有利于从心房颤动转变为主要不良心血管事件(危险比为0.92,0.87至0.98)、从心房颤动转变为心肌梗死(0.85,0.76至0.96)以及从心力衰竭转变为死亡(0.91,0.84至0.99):在普通人群中,定期服用鱼油补充剂可能是心房颤动和中风的一个风险因素,但对于心血管疾病从心房颤动发展为主要不良心血管事件,以及从心房颤动发展为死亡可能是有益的。要确定定期服用鱼油补充剂导致心血管疾病事件发生和预后的确切机制,还需要进一步的研究。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Regular use of fish oil supplements and course of cardiovascular diseases: prospective cohort study.

Objective: To examine the effects of fish oil supplements on the clinical course of cardiovascular disease, from a healthy state to atrial fibrillation, major adverse cardiovascular events, and subsequently death.

Design: Prospective cohort study.

Setting: UK Biobank study, 1 January 2006 to 31 December 2010, with follow-up to 31 March 2021 (median follow-up 11.9 years).

Participants: 415 737 participants, aged 40-69 years, enrolled in the UK Biobank study.

Main outcome measures: Incident cases of atrial fibrillation, major adverse cardiovascular events, and death, identified by linkage to hospital inpatient records and death registries. Role of fish oil supplements in different progressive stages of cardiovascular diseases, from healthy status (primary stage), to atrial fibrillation (secondary stage), major adverse cardiovascular events (tertiary stage), and death (end stage).

Results: Among 415 737 participants free of cardiovascular diseases, 18 367 patients with incident atrial fibrillation, 22 636 with major adverse cardiovascular events, and 22 140 deaths during follow-up were identified. Regular use of fish oil supplements had different roles in the transitions from healthy status to atrial fibrillation, to major adverse cardiovascular events, and then to death. For people without cardiovascular disease, hazard ratios were 1.13 (95% confidence interval 1.10 to 1.17) for the transition from healthy status to atrial fibrillation and 1.05 (1.00 to 1.11) from healthy status to stroke. For participants with a diagnosis of a known cardiovascular disease, regular use of fish oil supplements was beneficial for transitions from atrial fibrillation to major adverse cardiovascular events (hazard ratio 0.92, 0.87 to 0.98), atrial fibrillation to myocardial infarction (0.85, 0.76 to 0.96), and heart failure to death (0.91, 0.84 to 0.99).

Conclusions: Regular use of fish oil supplements might be a risk factor for atrial fibrillation and stroke among the general population but could be beneficial for progression of cardiovascular disease from atrial fibrillation to major adverse cardiovascular events, and from atrial fibrillation to death. Further studies are needed to determine the precise mechanisms for the development and prognosis of cardiovascular disease events with regular use of fish oil supplements.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
All cause and cause specific mortality in 15-24-year-olds in Denmark 2010 to 2022: nationwide study of socioeconomic predictors. Multimorbidity in emergency departments: urgent need for integrated care. Progressive pulmonary fibrosis: a need for real world data to solve real world clinical problems. Multimorbidity and adverse outcomes following emergency department attendance: population based cohort study. Predicting birth weight at booking.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1